Transgene shares gain 3% with financial visibility until 2028
The Strasbourg-based biotech's stock is rising sharply during the session in a well-oriented Paris market. This rebound follows a business update that specifies the group's financing horizon.
A rebound that brings the stock back to its moving averages
Transgene shares gain 3.12% to €0.76 during the session, while the CAC 40 rises 1.04%. The stock trades 7% above its MM20 (€0.71) and at the level of its MM50, while the MM200, at €0.78, remains 2.6% above the price and serves as the next obstacle, just below resistance at €0.778.
Over the week, the gain is only 1.6%, and the stock is still down nearly 36% over one year. The RSI at 58 remains neutral.
A business update that sets the financial horizon at early 2028
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On November 9, Transgene published its business update as of September 30. Cash reached €84.3 million compared with €111.9 million at the end of 2025, a consumption of €29.5 million over nine months, and the company confirms financial visibility until early 2028.
First results from the Phase 2 trial of TG4050, its individualized therapeutic vaccine, are expected by the end of the first quarter of 2028. Phase 1 data have just been published in Nature Communications, with 100% recurrence-free survival after more than three years.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Guidance from the release
Under current plans, the company has sufficient cash to ensure financial visibility until early 2028
Risks mentioned
L'activité repose sur le succès de essais cliniques en phase 1/2 pour TG4050 et TG4070, avec résultats finaux attendus fin Q1 2028
La dépendance à l'égard du crédit d'impôt recherche (CIR) : €3,9 M sur €4,3 M d'operating income, soit 91% de ce résultat
Consommation de trésorerie continue : €29,5 M en 9 mois 2026, limitant la visibilité au-delà de début 2028
Opportunities identified
Publication positive de TG4050 dans Nature Communications confirmant 100% DFS après 3+ ans, validant le modèle clinique
Expansion de la plateforme myvac® avec lancement de TG4070 en phase 1 combinée nivolumab dans le poumon (NSCLC)
Capacités de production en phase 3 prêtes fin 2027 et clarté financière jusqu'à début 2028 pour financer les développements
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
